



Malaria


Acute cerebral malaria treatment



Flourescence microscopy



No aptamer



With aptamer (10 µg/ml)

Disintegrated rosettes from falciparum parasite induced protein production

Molecule: 3 Aptamer fragments

Development stage: Preclinical stage, in-vitro tests on going in-vivo test.

Unmet need: No life saving treatment available

Treatment:

Inhibit protein production from falciparum parasites and disintegrate rosettes from protein production. Treatment works from first sign of infection.

Target group:

Malaria – Plasmodium falciparum. Patient target group – 2 million per year. According to WHO, there were an estimated 1 million malaria deaths in 2006.

Benefits:

Saves lives, works as a treatment and inhibitor.

Market:

According to WHO, an estimated US\$ 4.6 were available per malaria case in 26 out of 45 countries. This was however stated to be inadequate to meet targets for prevention and cure.

Intellectual property:

1 patent [05-02-2008] – Selection of RNA-aptamers as anti-malaria agents.

Strategy:

Out-licensing, spin-out.

Contact:

Dr. Bert Junno, Lund University Technology Group, +46-707-772209, bert.junno@forskarpatent.com

Dr. Mikael Lindstam, Lund University Technology Group, +46-766-333699, mikael.lindstam@forskarpatent.com